Veracyte, Inc.

NASDAQ:VCYT

Biotechnology

Healthcare
$25.57 +3.56%

+$1.83 today

Market cap
$2.06B
Beta
1.98
P/E (TTM)
48.0
EPS (TTM)
$1.11
52W Low $22.61High $53.66

Volume 2.45M

Average 1.05M

VCYT Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Veracyte, Inc.NASDAQ: VCYT

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q2 FY2026 weighted avg shares (diluted) of 82.23M shares rose 2.9% year over year, ahead of the +2.0% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 1.1% from the prior quarter. Over 3 fiscal years it compounded at +4.0% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +2.9% holds above the trailing-twelve-month pace of +2.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
82.23M+1.1% QoQ
Last fiscal yearDec 2025
80.57M+3.1% YoY
LTMJun 2026
81.15M+2.0% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.9%——
1 year+3.1%——
3-year CAGR+4.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
80.57M USD
Year-over-year change
+3.1%
4-year CAGR
+4.4%

Weighted Avg Shares (Diluted) vs competitors

How VCYT compares with its peers on the latest reported figures

  • VCYT's LTM Jun 2026 weighted avg shares (diluted) of 81.15M shares is the 5th highest of the 10 companies compared; the peer median is 49.5M shares.
  • Its year-over-year change of +2.0% is the 8th highest of 10, against a peer median of +5.9%.
  • Over three fiscal years its annual growth of +4.0% compares with a peer median of +16.0%.
VCYT Competitors Peer median
Weighted Avg Shares (Diluted) for VCYT and competitors
Company Period LTM YoY 3-year CAGR
GHGuardant Health, Inc.LTM Sep 2026131.61M +5.9%+7.1%
NEONeoGenomics, Inc.LTM Jun 2026129.14M +1.5%+1.0%
PSNLPersonalis, Inc.LTM Mar 202693.42M +36.5%+25.0%
MYGNMyriad Genetics, Inc.LTM Mar 202693.15M +2.4%+5.0%
VCYTVeracyte, Inc.LTM Jun 202681.15M +2.0%+4.0%
BLLNBillionToOne, Inc.LTM Jun 202649.5M +10.7%—
IMDXInsight Molecular Diagnostics Inc.LTM Mar 202632.26M +85.3%+76.5%
CSTLCastle Biosciences, Inc.LTM Mar 202629.46M +0.8%+3.6%
WGSGeneDx Holdings Corp.LTM Jun 202628.68M +2.4%+38.0%
BDSXBiodesix, Inc.LTM Mar 20268.14M +14.9%+53.1%
Peer median (excluding VCYT) 49.5M+5.9%+16.0%

Competitors are the stored peer set for VCYT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue219.51M296.54M361.05M445.76M517.15M
Cost of Revenue74.4M101.58M112.9M147.62M157.1M
Gross Profit145.11M194.95M248.15M298.15M360.05M
Gross Margin66.1%65.7%68.7%66.9%69.6%
Research & Development29.84M40.6M57.31M69.29M70.81M
Selling, General & Admin181.19M174.08M184.23M206.04M210.95M
Operating Expenses227.02M236.04M333.94M282M285.9M
Depreciation & Amortization19.59M25.93M27.19M23.46M21.42M
EBITDA(61.82M)(10.3M)(49.41M)49.21M89.62M
EBITDA Margin-28.2%-3.5%-13.7%11.0%17.3%
Operating Income(81.9M)(41.08M)(85.8M)16.14M74.15M
Operating Margin-37.3%-13.9%-23.8%3.6%14.3%
Interest Income135K1.97M7.34M11.15M0
Interest Expense241K198K15K2K0
Other Income / Expenses254K4.65M9.18M9.6M(5.95M)
Income Before Tax(81.65M)(36.43M)(76.61M)25.74M68.2M
Pre-Tax Margin-37.2%-12.3%-21.2%5.8%13.2%
Income Tax Expense(6.09M)133K(2.21M)1.61M1.85M
Net Income(75.56M)(36.56M)(74.4M)24.14M66.35M
Net Margin-34.4%-12.3%-20.6%5.4%12.8%
EPS (Basic)(1.11)(0.51)(1.02)0.320.84
EPS (Diluted)(1.11)(0.51)(1.02)0.310.82
Weighted Avg Shares67.89M71.55M72.64M76.48M78.58M
Weighted Avg Shares (Diluted)67.89M71.55M72.64M78.16M80.57M

Veracyte, Inc.

NASDAQ:VCYT

Intrinsic Alpha fair value

Locked

Current Price

$25.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.